Ubenimex

DB03424InvestigationalSmall molecule

Ubenimex (also known as bestatin) is a competitive protease inhibitor. It is an inhibitor of aminopeptidase B, leukotriene A4 hydrolase, aminopeptidase N. It is being studied for use in the... It is being studied for use in the treatment of acute myelocytic leukemia.

Chemical structure of Ubenimex
Primary indication
An adjuvant therapy used for acute and chronic myelonous leukemia, lung cancer and nasopharyngeal cancer.Curator reviewed
Formula / weight
C16H24N2O4 · 308.3728 g/mol (avg)

Resolves to

Compound
UNIII0J33N5627CAS58970-76-6ChEMBLCHEMBL29292PubChem72172
Structure
InChIKeyVGGGPCQERPFHOB-RDBSUJKOSA-NSMILESCC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1)C(O)=O
Targets
P09960LTA4HQ01693Bacterial leucyl aminopeptidase
Transporters
P46059SLC15A1Q16348SLC15A2

What you can answer from here — as of September 13, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
2TransportersSubstrate / inhibitor direction, not just membership
Listed above
56Drug interactionsStructured to mechanism, not free text
Sign in
5Clinical trialsPhase, status and sponsor resolved per trial
Sign in
21+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Ubenimex, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In